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Abstract   
Background In this study, survival and cause of death were investigated in patients 
with Crohn’s disease (CD) at a tertiary referral center. 
Methods A database was created based on the medical records of 1108 CD patients who 
had a history of visiting our hospital to investigate background characteristics, 
cumulative survival rates from diagnosis, causes of death, and the standardized 
mortality ratio (SMR) for each cause of death. A follow-up questionnaire survey of 
patients followed up inadequately was also conducted. The cumulative survival rate 
from diagnosis was determined using the life-table method and compared with that of a 
sex- and age-matched population model from the year 2000. 
Results The study included 1108 patients whose mean age at diagnosis was 25.6±10.8 
years. The mean duration of follow-up was 14.6±9.4 years, and there were 52 deaths. 
The cumulative survival rate was significantly lower 25 years after the diagnosis of CD 
(91.7%) than in the standard population model (95.7%). SMRs for both all causes (3.5; 
95% confidence interval [CI]: 2.7-4.6) and CD-specific causes (36.7; 95% CI: 
26.1-51.6) were high. Among the CD-specific causes, SMRs were especially high for 
small intestine and colorectal cancers, gastrointestinal diseases including intestinal 
failure (IF), perioperative complications, and amyloidosis. 
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Conclusion The SMRs for both all causes and CD-specific causes were high in CD 
patients. CD-specific causes including intestinal cancer, IF, perioperative complications, 
and amyloidosis showed especially high SMRs. 
 
Keywords 
Crohn’s disease-specific mortality, standardized mortality ratios, cohort study, intestinal 
cancer, amyloidosis 
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CD      Crohn’s disease 
CI      Confidence interval 
CRC     Colorectal cancer 
HPN     Home parenteral nutrition 
HR      Hazard ratio 
IBD     Inflammatory bowel disease 
ICD     International Classification of Diseases 
IF      Intestinal failure 
SMR    Standardized mortality ratio 
SIR     Standardized incidence ratio 
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Introduction 
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) of unknown 
etiology. It often develops at an early age and can affect the entire gastrointestinal tract 
from the oral cavity to the anus. It is also known to frequently require intestinal 
resection due to the development of intestinal complications such as stenosis and fistula 
through repeated relapses or recurrences.1)-4) Although there are some reports of the 
long-term course of patients with this disease, there are very few reports related to their 
survival and cause of death; moreover, most previous reports are derived from 
population-based cohort studies, and there are very few, long-term, hospital-based, 
cohort studies with a long duration of follow-up and a large sample size.5)-14) In the 
present study, a database based on the medical records of CD patients at our hospital 
with the addition of information obtained from a questionnaire survey was created, and 
the long-term prognosis of CD patients was investigated. 
 
Methods 
Study design and populations 
This was a single-center, retrospective, cohort study conducted at Fukuoka University 
Chikushi Hospital. Among the patients with a definitive diagnosis of CD who had a 
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history of visiting our hospital between May 1967 and December 2015, patients with a 
history of treatment for at least six months since diagnosis were selected, and a database 
based on their medical records was subsequently created.3) Patients who were followed 
up for less than six months after diagnosis were excluded. First, sex, age at diagnosis, 
date of diagnosis, smoking history, disease type at diagnosis, presence/absence of 
perianal disease, survival to the last observed day, surgical history, and use of 
medications (aminosalicylates, corticosteroids, thiopurines, and anti-tumor necrosis 
factor [TNF] agents) were determined from the medical records. Subsequently, a 
questionnaire survey of the patients who had not visited our hospital for at least three 
years was conducted between May 2015 and May 2016. 
In the present study, 1) the cumulative mortality of CD patients was compared with 
that of the standard population, 2) the causes of death in CD and the standardized 
mortality ratios (SMRs) by cause of death were investigated, and 3) background 
characteristics that affect mortality in CD patients were investigated. 
 
Duration of follow-up 
Duration of follow-up was defined as from the date of diagnosis to the last observed day. 
The date of diagnosis was determined based on medical records at our hospital, and the 
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last observed day was the date of the final visit to our hospital according to the medical 
records, or the date of survey response or date of death for patients whose information 
could be collected through the follow-up questionnaire survey. 
 
Ever-use of medicine 
The use of medications was reviewed for the duration of follow-up in all patients, and 
the use of aminosalicylates, corticosteroids, thiopurines, and anti-TNF agents was 
examined. Duration of medication use, dose, and side effects were not taken into 
consideration. 
 
Diagnosis and treatment of CD 
CD was diagnosed based on clinical symptoms, endoscopic findings, X-ray findings, 
and histological findings in accordance with the diagnostic criteria for CD proposed by 
the Japanese Ministry of Health, Labour and Welfare.15)-17) Furthermore, using the 
Montreal classification, disease location at diagnosis was classified into ileal type, 
colonic type, or ileocolonic type, and disease behavior at diagnosis was classified into 
inflammatory, stricturing, or penetrating type.18) 
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Assessment of mortality 
Date and cause of death were determined based on medical records, and those for the 
patients whose deaths were identified through the follow-up questionnaire survey were 
determined through an inquiry to the facility where they passed away. As in previous 
reports, the causes of death were classified in accordance with the International 
Classification of Diseases 10th revision (ICD-10).13)14)19) 
Gastrointestinal disease (excluding non-alcoholic liver disease, ICD codes 
K00-K70,77-93) included intestinal complications of CD such as intestinal obstruction 
and perforation, perioperative complications, state of undernutrition due to short-bowel 
syndrome, and sudden death of unknown cause that occurred during home parenteral 
nutrition (HPN) or the active stage of the disease. Non-alcoholic liver disease (ICD 
code: K71-76) included chronic and progressive liver diseases that were not considered 
associated with CD. 
There are no previous reports of the SMRs for deaths related to CD. Therefore, with 
the aim to calculate CD-specific mortality, the total mortality for small intestinal cancer 
(ICD code: C17), colorectal cancer (CRC) (ICD code: C18-21), and amyloidosis (ICD 
code: E85), as well as gastrointestinal diseases, as CD-specific causes was determined, 
and the numbers of expected cases of death and SMRs were calculated from the above 
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mortality and person-years in the sex- and age-matched population model. 
 
Statistical analysis 
1. Expected and observed cumulative survival rates from diagnosis 
The age by sex-specific death rates of the Japanese population in 2000 were applied to 
the distribution of the age groups of the study population by sex to estimate the yearly 
expected survival rate of the general population during the follow-up period. The death 
rates for 5-year age bands of both sexes were used in this study. According to the past 
reports, the age by sex-specific mortality of the Japanese population in 2000,20) which 
was almost the median of the year of diagnosis, was used.13) The life-table method was 
used to estimate the cumulative survival rate and 95% confidence intervals of the study 
subjects. 
2. SMRs of patients with CD 
The SMR is the ratio of the observed number of deaths among the patients with CD in 
this cohort study to the expected number of deaths in the study population under the 
assumption that the age by sex-specific mortality rates for the study population are the 
same as those for a reference population. The expected number of deaths was calculated 
by multiplying the person-years of the study population by the age by sex-specific death 
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rates of the Japanese population in 2000. The SMRs were calculated for 5-year age 
bands of both sexes in this study. 
3. Factors associated with mortality of patients with CD 
Hazard ratios of death and their 95% confidence intervals were estimated with a Cox 
proportional hazards model. Age was treated as a continuous variable, while other 
factors were treated as indicator variables.  
4. Number of intestinal resections and mortality in patients with CD 
Number of intestinal resection was classified into three categories: 0, 1-4, 5 or more. A 
chi-squared test was used to evaluate if the number of intestinal resections was related 
to the death rate. The dose-dependent trend was tested by evaluating the regression 
coefficient when the categories were treated as equally spaced numerical variables in 
Cox’s model 
Person-years at risk were computed from the date of CD diagnosis until the date of 
death, loss to follow-up, or end of follow-up. 
All statistical analyses were conducted using the Statistical Analysis System (SAS 
Institute, Cary, NC, USA) package. A two-sided P less than 0.05 was considered 
significant. 
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Ethical considerations 
This study was conducted in accordance with the 1964 Helsinki Declaration and its 
subsequent amendments. Personal information listed in the medical records or obtained 
through questionnaire surveys, including informed consent, was managed on a database 
such that individuals were anonymized. This study was approved by the institutional 
review board of Fukuoka University Chikushi Hospital (R14-011, 2014.6.4-2017.2.28). 
 
Results 
Patient populations and background characteristics 
This study included 1108 patients whose duration of follow-up was at least six months 
from among the 1165 CD patients who were diagnosed after May 1967 and had a 
history of visiting our hospital to December 2015. A questionnaire survey was 
distributed to 303 CD patients who did not have a history of visiting our hospital for at 
least 3 years, and information on their present condition (alive, dead), cause of death, 
last observed day, smoking history, surgical history, and previously used medications 
were added from the 106 responses. It was therefore possible to obtain information on 
background characteristics and survival to the last observed day for all patients. The 
patients’ clinical characteristics are shown in Table 1. There were 758 men and 350 
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women who were 7-76 years old at the time of diagnosis. The mean age at diagnosis 
was 25.6±10.8 years, and the mean duration of follow-up was 14.6±9.4 years (range: 
0.5-47.2 years). The study included 16,199 person-years, and 583 patients (52.6%) were 
diagnosed before 2000. Disease location at diagnosis was ileal type in 386 patients 
(34.8%), colonic type in 197 patients (17.8%), and ileocolonic type in 525 patients 
(47.4%). Disease behavior was inflammatory in 531 patients (47.9%), stricturing in 365 
patients (32.9%), penetrating in 208 patients (18.8%), and unknown in 4 patients (0.4%). 
A perianal fistula was present at diagnosis in 594 patients (53.6%). There were 303 
current smokers (27.3%), 610 never-smokers (55.1%), and 117 ex-smokers (10.6%). 
There were 662 patients (59.7%) who had undergone intestinal surgery by the last 
observed day. The mean number of surgeries per patient was 1.2±1.4. Previously-used 
medications included aminosalicylates in 864 patients (77.9%), corticosteroids in 346 
patients (31.2%), thiopurines in 423 patients (38.1%), and anti-TNF agents in 570 
patients (51.4%). 
 
Overall mortality 
Fifty-two deaths occurred among the 1108 patients with CD. Among the 52 deaths, nine 
were reported through the additional questionnaire survey. The background 
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characteristics of the deceased patients are shown in Table 2. Of the 52 patients who 
died, 32 were men (61.5%). The mean age at diagnosis was 29.1±14.0 years, the mean 
age at death was 48.1±14.6 years, and the mean duration of follow-up from diagnosis to 
death was 18.3±8.8 years. Disease location at diagnosis was ileal type in 15 patients 
(28.9%), colonic type in 6 patients (11.5%), and ileocolonic type in 31 patients (59.6%). 
Disease behavior at diagnosis was inflammatory in 21 patients (40.4%), stricturing in 19 
patients (36.5%), and penetrating in 12 patients (23.1%). There were 31 patients 
(59.6%) presenting with perianal disease, 2 current smokers (3.9%), and 45 patients 
(86.5%) who had undergone surgery during the follow-up period. The mean number of 
surgeries per patient was 2.3±1.8. Previously-used medications were aminosalicylates in 
29 patients (55.8%), corticosteroids in 26 patients (50.0%), thiopurines in 12 patients 
(23.1%), and anti-TNF agents in 21 patients (40.4%). 
 
Expected and observed cumulative survival rates from diagnosis 
The cumulative survival rates from diagnosis in CD patients are shown in Figure 1. The 
cumulative survival rates among CD patients were 99.3% (95% CI: 98.8-99.9) after 10 
years (expected cumulative survival rate: 98.3%, 95% CI: 97.5-99.0%), 95.1% (95% CI: 
93.3-96.9%) after 20 years (expected cumulative survival rate: 96.5%, 95% CI: 
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95.5-97.6%), and 87.1% (95% CI: 82.8-91.4%) after 30 years (expected cumulative 
survival rate: 94.9%, 95% CI: 93.6-96.1%)．The cumulative survival rate of CD patients 
in the first 24 years since diagnosis was not different from that of the standard 
population model. However, it was significantly lower in CD patients (91.7%; 95% CI: 
89.0-94.4%) at 25 years after diagnosis compared to that in the standard population 
model (95.7%; 95% CI: 94.5-96.9%), and this pattern continued thereafter. 
 
Causes of death in CD and the SMRs by cause of death 
The numbers of deaths and SMRs by cause of death in CD patients are shown in Table 3. 
Fifty-two of the 1108 CD patients died. The causes of death were: malignant tumor 
(n=19; small intestinal cancer, n=2; CRC, n=11; lung cancer, n=2; lymphoma, n=2; 
brain tumor, n=1; and cancer of unknown primary, n=1), gastrointestinal disease (n=15), 
liver disease (n=3), respiratory disease (n=2), cardiovascular disease (n=3), suicide 
(n=3), metabolic disease (n=5), and traffic injuries (n=1). Information about the cause of 
death was not provided on the questionnaire survey in one case. There were a total of 33 
deaths related to CD, including small intestinal cancer, CRC, gastrointestinal disease, 
and amyloidosis (pathologically secondary amyloidosis as shown by immunostaining 
AA amyloid). Gastrointestinal disease (n=15) consisted of intestinal failure (IF) (n=7), 
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severe (fistulous) disease including perioperative complications (n=6), and intestinal 
perforation (n=2). Amyloidosis (n=5) consisted of kidney failure (n=3) and massive 
bleeding (n=2). 
 
SMRs 
Fifty-two all-cause deaths were observed in this study, while the expected value 
calculated from the mortality in the sex- and age-matched general population was 14.8. 
Thus, the SMR for all-cause mortality was 3.5 (95% CI: 2.7-4.6). 
Analysis by disease revealed a high SMR of 5.4 (95% CI: 3.5-8.5) for malignant 
tumors. SMRs were especially high for small intestinal cancer at 200 (95% CI: 
500.1-7997.1), CRC at 29.7 (95% CI: 16.5-53.7), and brain tumor at 12.5 (95% CI: 
1.8-88.7). In addition, SMRs were also high for gastrointestinal disease at 48.4 (95% 
CI: 29.2-80.3), non-alcoholic liver disease at 14.3 (95% CI: 4.6-44.3), and amyloidosis 
at 1000 (95% CI: 416.2-2402.6). However, high SMRs were not observed for many 
conditions, such as respiratory disease (1.4; 95% CI: 0.4-5.7), cardiovascular disease 
(1.3; 95% CI: 0.4-3.9), suicide (1.2; 95% CI: 0.4-3.6), and traffic injuries (0.7; 95% CI: 
500.1-7997.1). The SMR for CD-specific causes of death, which included small 
intestinal cancer, CRC, gastrointestinal disease, and metabolic disease, was high at 36.7 
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(95% CI: 26.1-51.6). 
Thus, the results showed that many deaths of CD patients were caused by intestinal 
cancer, IF, severe (fistulous) disease including perioperative complications, and 
amyloidosis. 
 
Factors associated with mortality in patients with CD 
Factors associated with mortality are shown in Table 4. Sex, calendar year, disease 
location and behavior at diagnosis, smoking habits, perianal fistula, thiopurines, and use 
of anti-TNF agents were not significant factors. However, old age at diagnosis (≥60 
years) (hazard ratio [HR] 19.93; 95% CI: 5.56-71.54) and use of corticosteroids (HR 
1.94; 95% CI: 1.12-3.25) had high HRs. 
 
Number of intestinal resections and the death rate 
The number of intestinal resections and the death rate in all subjects and in patients 
followed up more than 25 years were examined (Table 5). A higher number of surgeries 
was significantly associated with higher mortality during the entire follow-up period 
(Table 5-1, p<0.01 by chi-squared test, p for trend<0.01), as well as in patients who 
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were followed up for 25 years and more (Table 5-2, p=0.03 by chi-squared test, p for 
trend=0.02). 
 
Discussion 
The results of long-term follow-up of CD patients in the present study showed that the 
cumulative survival rate decreased and SMR increased ≥25 years after diagnosis. 
Among individual complications, CD-specific causes, such as intestinal cancer, IF, 
severe (fistulous) diseases including perioperative complications, and amyloidosis, 
developed ≥20 years after diagnosis, increasing mortality. 
There are several reports primarily from Western countries concerning the survival 
and causes of death of CD patients. It has recently been reported that mortality is similar 
or slightly higher in CD patients than in the general population.5)-14) However, most data 
are derived from population-based studies, which are considered not conducive to 
patient follow-up or detailed investigation of the causes of deaths, and there are very 
few, long-term, hospital-based studies with a large sample size.5)6)14)21)-25) Therefore, this 
hospital-based cohort study was conducted at a tertiary referral center in Japan to 
investigate survival, cause of death, and factors that affect mortality of CD patients in 
detail. 
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The cumulative survival rates of CD patients from diagnosis were 98.9% at 10 years, 
94.0% at 20 years, and 86.7% at 30 years according to Lee et al. from Korea,14) and the 
rates were generally consistent with the results of the present study. Some reports 
compared the cumulative survival rate from diagnosis with that of the standard 
population model and found no significant differences between the two groups.5)8)11) 
Consistent with previous reports, the present study results also did not show significant 
differences for 25 years from diagnosis. However, longer follow-up demonstrated that 
the cumulative survival rate decreased significantly ≥25 years from diagnosis. These 
findings suggest that long-term follow-up of 20 years or longer may show a decrease in 
cumulative survival among CD patients. 
Table 6 shows SMRs for all causes from previous hospital-based studies.5)6)14)21)-25) 
Prior et al. (1981) and Weterman et al. (1990) reported high SMRs, but recent reports 
did not find increased SMRs. Except for the study by Lee et al., previous reports 
encompassed a low number of person-years (range: 2712-7424), which takes into 
account the number of patients and the duration of follow-up. Furthermore, compared to 
the report by Lee at al., the present study had a longer mean duration of follow-up (14.6 
years) with 16,197 person-years. It is evident from Figure 1 that the cumulative survival 
rate >25 years after diagnosis was decreased, indicating that the present study might be 
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informative, since there are no other studies with both high person-years at risk and a 
long duration of follow-up. 
Regarding SMRs by disease, previous reports showed that SMRs were high for 
neoplasms, especially small intestinal cancer and CRC, as well as gastrointestinal 
diseases.13)14)26)27) As in previous studies, the present study also found high SMRs for 
malignant tumors, especially small intestinal cancer and CRC, as well as gastrointestinal 
disease and amyloidosis, and not very high SMRs for respiratory and cardiovascular 
disease. The SMR of all causes was high in the present study, likely because of the high 
SMR for CD-specific causes. 
In the present study, the SMR for gastrointestinal disease was high, because the data 
showed that the number of intestinal resections was significantly related to the death 
rate (Table 5). CD induces intestinal complications over the long course of the disease, 
requiring repeated surgeries. Frequent surgeries and intestinal complications can result 
in short bowel syndrome and IF. According to Watanabe et al., IF was observed 
relatively frequently at a specialized hospital, with an incidence of 3.6% at 10 years and 
8.5% at 20 years after initial surgery for CD, and the mortality after diagnosis of IF was 
3.7% at 5 years and 8.9% at 10 years.28) HPN-related mortality according to reports 
from overseas ranges from 2 to 28% at 5 years, which is by no means low.29) Loly et al. 
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collected data from numerous cases and stated that the mortality of CD patients who 
received HPN was 10% at 5 years, and Limketkai et al. stated that mortality caused by 
IF was 6% at 1 year and up to 20% at 4 years.30)31) It could be expected that mortality 
due to intestinal complications, as well as short bowel syndrome and IF caused by such 
complications, would be high, and the SMR for gastrointestinal disease is considered to 
be high, similar to previous reports. 
Malignant tumors had the second highest SMR in the present study. Recently, Caini 
et al. from Italy conducted long-term follow-up of 231 CD patients and compared 
SMRs by causes of death. Their results showed that the SMR was 1.79 for all causes 
(95% CI: 1.39-2.27), and it was very high for cancer, at 2.57 (95% CI: 1.28-5.13).32) 
Furthermore, most reports have demonstrated that the SMR is higher for lower 
gastrointestinal cancer among malignant tumors. Reports from Western countries have 
shown the standardized incidence ratio (SIR) to be 2.5 (95% CI: 1.3-4.7) for CRC and 
33.2 (95% CI: 15.9-60.9) for small bowel cancer.33) It has also been reported in Japan 
that the SIR for CRC is 2.79-5.8.34)35) Higashi et al. reported that the frequency of 
comorbid CRC in CD from multiple facilities specialized for IBD was 3.5% (122/3454 
patients), and that the 5-year survival rate of CRC was 88% in Stage I, 68% in Stage II, 
71% in Stage IIIa, 25% in Stage IIIb, and 0% in Stage IV.36) Of these cases, 91% of the 
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diagnosed gastrointestinal cancers were advanced cancers. In addition, they claimed that 
comorbid CRC has increased markedly in Japan since 2008. Sugita et al. analyzed 20 
CD patients with rectal and anal cancers, and they reported a mortality of 33% after 36 
months.37) As described here, the incidences of intestinal cancer and anal cancer have 
also increased in Japan, and mortality associated with these diseases is not low. 
One of the major differences between this study and previous reports is that the SMR 
for amyloidosis was very high. The prevalence of comorbid secondary amyloidosis in 
patients with CD has been reported to be 2.5-5.3% in Japan and 0.9%-5.6% in Western 
countries.38)-42) It is considered that, when amyloidosis develops in conjunction with CD, 
serious complications including kidney failure ensue, ultimately increasing mortality.42) 
A recent study from the USA showed that mortality increases in the presence of 
secondary amyloidosis in hospitalized CD patients.41) A report by Miyaoka from Japan 
stated that secondary amyloidosis does not occur frequently in CD (2.5%), but that 40% 
of these patients died, indicating that the prognosis is poor with secondary 
amyloidosis.40) In addition, a long-term outcome report by Weterman et al. showed that 
4 of 64 deaths (6.3%) were due to amyloidosis,22) indicating that this is not rare. Patients 
are diagnosed with amyloidosis between 12.0 and 25.0 years after the diagnosis of 
CD,38)40)43) and they die of complications such as kidney failure. Thus, death caused by 
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amyloidosis may only be captured by performing long-term follow-up, as demonstrated 
in the present study. 
The limitations of this study are as follows. It is very difficult to obtain long-term 
outcomes including mortality rates in a cohort group, because CD patients have younger 
disease onset, and follow-up for more than 20 years is extremely difficult due to their 
higher social activity and frequent changes in residence. Because we have an affiliated 
hospital network and added a questionnaire survey, we succeeded in gathering sufficient 
data related to mortality and cause of death over a long term. 
Because the present study was a retrospective cohort study, disease location and 
behavior observed at initial examination were not significant factors associated with 
mortality. Furthermore, while the usefulness of anti-TNF-α agents and a decrease in the 
intestinal resections performed for refractory CD have been suggested recently, there 
was no association with the use of medications.44)-47) Nutritional therapy was not 
considered in the present study; it was considered difficult to elucidate the contribution 
of nutritional therapy to mortality since the data were old and retrospective, and the 
dose and duration of the therapy were not known in many of the patients. Further 
investigations will be necessary to clarify the associations with treatment and changes in 
disease type. 
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Conclusion 
The long-term follow-up of CD patients in the present study showed that the cumulative 
survival rate decreases and SMR increases ≥25 years after diagnosis. Among individual 
complications, CD-specific causes such as intestinal cancer, IF, severe (fistulous) 
diseases including perioperative complications, and amyloidosis developed ≥20 years 
after diagnosis, increasing mortality. In the future, it may be possible to improve the 
prognosis by predicting these serious complications or by diagnosing them at an early 
stage. 
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Figure legends 
Figure 1. Expected and observed cumulative survival rates from diagnosis in 1108 
patients with CD. Although the cumulative survival rate at 25 years from diagnosis is 
not different compared to that of the standard population model, it is significantly lower 
≥25 years after diagnosis. 
 
Sex (male/female) 758 / 350
Age at diagnosis (mean±SD, years) 25.6±10.8  (7-76)
Follow-up period (mean±SD, years) 14.6±9.4    (0.5-47.2)
Calendar year at diagnosis
<2000
≥2000
583 (52.6%)
525 (47.4%)
Disease location at diagnosis*
Ileal
Colonic
Ileocolonic
386 (34.8%)
197 (17.8%)
525 (47.4%)
Disease behavior at diagnosis*
Inflammatory
Stricturing
Penetrating
Unknown
531 (47.9%)
365 (32.9%)
208 (18.8%)
4      (0.4%)
Perianal disease at diagnosis
Absent
Present
514 (46.4%)
594 (53.6%)
Smoking at last observed day
Never-smoker
Ex-smoker
Current smoker
Unknown
610 (55.1%)
117 (10.6%)
303 (27.3%)
78   (7.0%)
Intestinal resection at last observed day
Absent
Present
Number of intestinal resections (mean±SD)
446 (40.3%)
662 (59.7%)
1.2±1.4 (0-7)
Ever-use of medication
Aminosalicylates
Corticosteroids
Thiopurines
Anti-TNF agents
864 (77.9%)
346 (31.2%)
423 (38.1%)
570 (51.4%)
Table 1. Characteristics of patients with Crohn’s disease (n=1108)
*Disease location and behavior at diagnosis are according to the Montreal classification.
SD, standard deviation; TNF, tumor necrosis factor.
Table 2. Background characteristics of deceased patients (n=52)
Sex (male) 32 (61.5%)
Age at diagnosis (mean±SD, years) 29.1±14.0
Age at death (mean±SD, years) 48.1±14.6
Duration of follow-up (mean±SD, years) 18.3±8.8
Disease location at diagnosis*
Ileal
Colonic
Ileocolonic
15 (28.9%)
6   (11.5%)
31 (59.6%)
Disease behavior at diagnosis*
Inflammatory
Stricturing
Penetrating
21 (40.4%)
19 (36.5%)
12 (23.1%)
Perianal disease at diagnosis 31 (59.6%)
Smoking at last observed day
Never-smoker
Ex-smoker
Current smoker
Unknown
38 (73.1%)
11 (21.1%)
2 (3.9%)
1    (1.9%)
Intestinal resection at last observed day
Present
Number of intestinal resections (mean±SD) 
45 (86.5%)
2.3±1.8  (0-7)
Ever-use of medication
Aminosalicylates
Corticosteroids
Thiopurines
Anti-TNF agents
29 (55.8%)
26 (50.0%)
12 (23.1%)
21 (40.4%)
SD, standard deviation; TNF, tumor necrosis factor.
*Disease location and behavior at diagnosis are according to the Montreal classification.
Cause ICD-10 
code
Observed
cases
Expected 
cases
SMR 95% CI
All causes 52 14.8 3.5 2.7-4.6
Malignant tumor C00-D48 19 3.5 5.4 3.5-8.5
Small intestinal cancer* C17 2 0.01 200 500.1-7997.1
Colorectal  cancer* C18-C21 11 0.37 29.7 16.5-53.7
Lung cancer C33-C34 2 0.45 4.4 1.1-17.8
Lymphatic cancer C81-C96 2 0.72 2.8 0.7-11.1
Brain tumor C70-C72 1 0.08 12.5 1.8-88.7
Cancer of unknown primary - 1 - - -
Gastrointestinal disease*
(excluding K71-76)
K00-
70,77-93
15 0.31 48.4 29.2-80.3
Non-alcoholic liver disease K71-76 3 0.21 14.3 4.6-44.3
Respiratory disease J00-J99 2 1.4 1.4 0.4-5.7
Cardiovascular disease I00-I99 3 2.4 1.3 0.4-3.9
Suicide X60-X84 3 2.6 1.2 0.4-3.6
Metabolic disease
(amyloidosis)*
E85 5 0.005 1000 416.2-2402.6
Traffic injuries V00-V89 1 1.4 0.7 0.1-5.1
Unknown - 1 - - -
CD-specific  causes* 33 0.9 36.7 26.1-51.6
Table 3. All causes of death in Crohn’s disease patients and standardized mortality ratios
by cause of death
*CD-specific causes are small bowel and colorectal cancer, gastrointestinal disease, and 
amyloidosis.
ICD-10, International Classification of Diseases-10; SMR, standardized mortality ratio. 
CI, confidence interval.
Data at the baseline survey Person-years No. of cases Age- and sex-adjusted HR 
(95% CI)
Sex
Female
Male
5438
10759
20
32
1.00  (reference)
0.97  (0.55-1.07)
Age (years)
< 20 
20-59
≥ 60
5549
10505
142
14
35
3
0.64  (0.34-1.19)
1.00  (reference)
19.93 (5.56-71.54)
Calendar year 
< 1999
≥ 2000
12126
4071
47
5
1.00  (reference)
0.61  (0.21-1.74)
Disease location at diagnosis
Ileal 
Colonic＋ileocolonic 
5859
10338
15
37
0.57  (0.31-1.05)
1.00  (reference)
Disease behavior at diagnosis
Inflammatory
Stricturing＋penetrating
6795
9335
15
37
1.03 (0.59-1.80)
1.00  (reference)
Perianal disease
Absent
Present
6558
9639
21
31
1.00  (reference)
1.07  (0.60-1.90)
Smoking habits
Never-smoker＋ex-smoker
Current smoker
10619
4649
40
11
1.00  (reference)
0.77  (0.38-1.52)
Intestinal resection
Absent
Present
4273
11925
7
45
1.00  (reference)
1.47  (0.65-3.35)
Ever-use of medicine
Corticosteroids
Without
With
Thiopurines
Without
With
Anti-TNF agents
Without
With
10502
5509
9868
6184
7945
8253
26
26
40
12
31
21
1.00  (reference)
1.94  (1.12-3.25)
1.00  (reference)
0.59 (0.30-1.13)
1.00  (reference)
0.87 (0.49-1.55)
Table 4. Factors associated with mortality of Crohn’s disease patients
HR, hazard ratio; CI, confidence interval; TNF, tumor necrosis factor.
Number of intestinal resections
p for trend **
Present condition 0 1-4 ≥5
n=446 n=620 n=42
Dead (n=52) 7 (1.6%) 36 (5.8%) * 9 (21.4%) * <0.01
Number of intestinal resections
p for trend **
Present condition 0 1-4 ≥5
n=24 n=137 n=23
0.02Dead (n=12) 0 (0.0%) 8 (5.8%) 4 (17.4%) *
Table 5. Number of intestinal resections and death rates by follow-up period
Table 5-1. Death rate and number of intestinal resections in all subjects (total observation period)
Table 5-2. Death rate and number of intestinal resections in patients observed more than 25 years
* Chi-squared test
* Chi-squared test
Data  was presented as n (%)
* p=0.03 vs no intestinal resection 
Data  was presented as n (%)
* p<0.01 vs no intestinal resection 
** Regression coefficient using Cox’s model
** Regression coefficient using Cox’s model
Author Year Country Years of diagnosis
Follow-up 
period  (years)
Cases Deaths SMR 95% CI %Death
Person-years
at risk
Prior 1981 UK 1941-1976 14.5 513 102 2.0 1.85-2.47 19.9 7424
Weterman 1990 Netherlands 1934-1984 9.9 659 64 2.2 1.75-2.85 9.7 6590*
Cottone 1996 Italy 1973-1993 7.8 531 9 1.0 0.4-1.8 1.7 2712
Farrokhyar 2001 UK 1978-1986 15.0 196 23 0.9 0.59-1.4 11.7 3623
Uno 2003 Japan 1967-1997 8.4 544 6 1.4 0.53-3.12 1.1 4570*
Oriuchi 2003 Japan 1965-1998 9.9 276 11 N.D** N.D** 4.0 2732*
Kennedy 2012 Scotland 1998-2000 3.0 1595 144 3.3 2.8-3.89 9.0 4785*
Lee 2017 Korea 1981-2013 8.6 2414 35 1.4 0.97-1.94 1.4 20712
Yasukawa Japan 1968-2015 14.6 1108 52 3.5 2.7-4.6 4.7 16199
* Person-years at risk were estimated by the author (cases×follow-up periods).
** N.D: no data in the publication.
SMR, standardized mortality ratio; CI, confidence interval.
Table 6. Hospital-based studies examining mortality in Crohn’s disease

